Wells Fargo & Company Centessa Pharmaceuticals PLC Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Wells Fargo & Company holds 520 shares of CNTA stock, worth $8,242. This represents 0.0% of its overall portfolio holdings.
Number of Shares
520Holding current value
$8,242% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CNTA
# of Institutions
83Shares Held
96.6MCall Options Held
12.1KPut Options Held
3K-
Medicxi Ventures Management (Jersey) LTD20MShares$316 Million64.35% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$158 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$153 Million2.77% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.71MShares$90.6 Million1.82% of portfolio
-
First Light Asset Management, LLC Edina, MN4.78MShares$75.8 Million3.93% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.5B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...